The abstract will be presented today, October 27th, 2025, by Dr. Patricio M Polanco, Professor in the Division of Surgical Oncology and co-director of the Pancreatic Cancer Program and the Pancreatic Cancer Prevention Clinic at the University of Texas Southwestern Medical Center.

The abstract, titled “High Performance of a Blood-Based Biomarker Test to Detect Early-Stage Pancreatic Cancer in a High-Risk Population, Across Two Independent Clinical Validation Studies", was selected by peer reviewers for a prominent plenary presentation. It was also designated as a “newsworthy” abstract to be shared with media members attending the 2025 ACG Annual Scientific Meeting.

“I am pleased to be presenting data showing the consistent and strong performance of PancreaSure in detecting early-stage pancreatic cancer in patients at high risk across two independent clinical studies,” said Dr Patricio M Polanco. “Having effective tools for the early detection of pancreatic cancer is key to impacting patient outcomes in this disease.”

The abstract is based on combined data from Immunovia’s two primary clinical validation studies, CLARITI and VERIFI. The studies confirmed the accuracy of the test for early-stage detection, with a sensitivity of 78% and specificity of 92% in detecting Stage 1 and Stage 2 pancreatic cancer across over 1400 patients.

ACG’s Annual Scientific Meeting & Postgraduate Course is taking place October 24–29, 2025 in Phoenix, Arizona. It brings together clinicians, academicians, researchers, trainees, advanced practice providers, and other professionals in the field of gastrointestinal medicine. The meeting offers in-depth discussions, presentations, exhibits, education, and networking opportunities.